Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative

American Journal of Cardiology

Volumn 85, Issue 3 SUPPL. 1, 2000, Pages 23-29

  Labresh, Kenneth A ^a   Owen, Patricia ^a   Alteri, Catherine ^a   Reilly, Susan ^a   Albright, Patricia Shea ^a   Hordes, Andrew R ^a,b   Shaftel, Peter A ^a,b   Noonan, Thomas E ^a,b   Stoukides, Cheryl A ^c   Kaul, Alan F ^c  

^a Blackstone Cardiology Associates   (United States)

^b BROWN UNIVERSITY   (United States)

^c Medical Outcomes Management Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; GROUP PRACTICE; HOSPITAL CARE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CARDIOLOGY; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; GROUP PRACTICE; HEALTH EDUCATION; HOSPITALS, UNIVERSITY; HUMANS; HYPERLIPIDEMIAS; INPATIENTS; MALE; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 0033973898     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00935-2     Document Type: Article

References (28)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
3. Superko H.R., Krauss R.M., DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol. 80:1997;78-81.
4. Smith S.C. Jr, Blair S.N., Criqui M.H., Fletcher G.F., Fuster V., Gersh B.J., Gotto A.M., Gould K.L., Greenland P., Grundy S.M. AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. J Am Coll Cardiol. 26:1995;292-294.
5. Smith S.C. Jr, Blair S.N., Criqui M.H., Fletcher G.F., Fuster V., Gersh B.J., Gotto A.M., Gould K.L., Greenland P., Grundy S.M. Preventing heart attack and death in patients with coronary disease. Circulation. 92:1995;2-4.
6. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-1445.
7. Simpson R.J. Jr. Performance assessment model for guideline recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction. Am J Cardiol. 80:(suppl 8B):1997;53H-56H.
8. Allison T.G., Squires R.W., Johnson B.D., Gau G.T. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients importance of diet, exercise, weight control, and drug therapy . Mayo Clin Proc. 74:1999;466-473.
9. Keilson L. Lipid and risk factor management in the hospital setting an opportunity to prevent recurrent disease . Issues Prev Cardiol. 1.3:1998;2-7.
10. Frolkis J.P., Zyzanski S.J., Schwartz J.M., Suhan P.S. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines. Circulation. 98:1998;851-855.
11. Avorn J., Monette J., Lacour A. Persistence of use of lipid lowering medications a cross-national study . JAMA. 279:1998;1458-1462.
12. Grover S.A., Coupal L., Paquet S., Zowall H. Cost effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med. 159:1999;593-600.
13. Elliott W.J., Weir D.R. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Sys Pharm. 56:1999;1726-1732.
14. Hay J.W., Yu W.M., Ashraf T. Pharmacoeconomics of lipid lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 15:1999;47-74.
15. Cleeman J.I., Lenfant C. The National Cholesterol Education Program. JAMA. 280:1998;2099-2104.
16. Bramlet D.A., King H., Young L., Witt J.R., Stoukides C., Kaul A.F. Management of hypercholesterolemia practice patterns for primary care providers and cardiologists . Am J Cardiol. 80:(suppl 8B):1997;39H-44H.
17. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., Houston-Miller N., Kris-Etherton P., Krumholz H.M., LaRosa J., et al. When to start cholesterol-lowering therapy in patients with coronary heart disease a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction . Circulation. 95:1997;1683-1685.
18. Schrott H.G., Bittner V., Vittinghoff E., Herrington D.M., Hulley S. Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease the heart and estrogen/progestin replacement study (HERS) . JAMA. 277:1997;1281-1286.
19. Stafford R.S., Blumenthal D., Pasternak R.C. Variations in cholesterol management practices of US physicians. J Am Coll Cardiol. 29:1997;139-146.
20. Eaton C.B., McQuade W., Glupczynski D. A comparison of primary versus secondary cardiovascular disease prevention in an academic family practice. Fam Med. 26:1994;587-592.
21. Cohen M.V., Byrne M.J., Levine B., Gutowski T., Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 83:1991;1294-1304.
22. Meyers D.G., Steinle B.T. Lipid screening and treatment by cardiologists have not improved. Kans Med. 97:1997;14-17.
23. McBride P.E., Schrott H.G., Plane M.B., Underbakke G., Brown R.L. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease. Arch Intern Med. 158:1998;1238-1244.
24. Shaffer J., Wexler L.F. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care . Arch Intern Med. 155:1995;2330-2335.
25. Harris D.E., Record N.B., Gipson G.W., Pearson T.A. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol. 81:1998;929-933.
26. Campbell N.K., Ritchiel L.D. Secondary prevention in coronary heart disease a randomized trial of nurse led clinics in primary care . Heart. 80:1998;447-452.
27. Hoerger T.J., Bala M.V., Bray J.W., Wilcosky T.C., LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment eligible United States adults. Am J Cardiol. 82:1998;61-65.
28. Sueta C.A., Chowdhury M., Boccuzzi S.J., Smith C., Alexander C.M., Londhe A., Lulla A., Simpson R.J. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.